Tag: GlobeNewswire

New York, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has hired Jennifer Charlton, Ph.D., as its Vice President of Fuel Technology.

Dr. Charlton brings nearly two decades of experience in nuclear materials, uranium processing, fuel-cycle technology, and advanced manufacturing to NANO Nuclear. Prior to joining NANO Nuclear, Dr. Charlton held several senior technical and leadership positions at the Y-12 National Security Complex. Notably, she served as Chief Scientist and U.S. Lead for Nuclear Material Verification, leading technical initiatives and providing comprehensive technical expertise across the nuclear fuel cycle, from uranium mining and milling through conversion, enrichment, fuel fabrication, and finished fuel and weapons component operations.

“NANO Nuclear’s strategic focus on building capabilities across key areas of the nuclear fuel cycle is an important part of supporting its long-term microreactor deployment strategy,” said Jennifer Charlton, Ph.D., Vice President of Fuel Technology of NANO Nuclear Energy. “I’m excited to join the team at this important stage of its growth and leverage my experience leading complex technical initiatives to help advance this strategy and strengthen NANO Nuclear’s capabilities across the fuel cycle.”

Figure 1 – NANO Nuclear Energy Hires Former Y-12 Leader and Nuclear Fuel Cycle Expert, Jennifer Charlton Ph.D. as its Vice President of Fuel Technology.

Dr. Charlton earned a Ph.D. in Chemistry from the University of Tennessee, a Bachelor of Science in Chemistry from the University of North Florida, and an Associate of Arts from Florida State College. Her graduate research encompassed automated radiochemical separations, nanofabrication, surface-enhanced spectroscopy, mass spectrometry, instrumentation development, nuclear forensics, trace-level materials analysis, and materials characterization.

“It is a pleasure to welcome Dr. Charlton to the NANO Nuclear team,” said Jay Yu, Founder and Chairman of NANO Nuclear Energy. “Her addition marks another step towards ensuring that we have the right personnel to oversee NANO Nuclear’s long-term strategic focus on vertical integration. Her experience within the Y-12 National Security Complex will be invaluable as we look to expand our capabilities across the nuclear fuel cycle.”

Dr. Charlton joins a growing list of former senior nuclear leaders and builds on NANO Nuclear’s recently announced addition of Marylin Diaz to support the Company’s expansion across the nuclear fuel cycle. In her role as Vice President of Fuel Technology, Dr. Charlton will be responsible for evaluating opportunities to expand NANO Nuclear’s capabilities across the nuclear fuel cycle and leading the design, engineering, and development of related technologies, with a focus on the uranium conversion, deconversion, and fuel fabrication processes. She will also provide technical expertise to inform strategic decisions regarding NANO Nuclear’s broader vertical integration strategy in support of future advanced reactor deployments and nuclear logistics activities.

“As our core, proprietary technology, the KRONOS MMR^™ Energy System, continues along its development pathway, we are working to expand across the nuclear fuel cycle to help de-risk the marketplace as well as support the energy sovereignty of the United States,” said James Walker, Chief Executive Officer of NANO Nuclear Energy. “Dr. Charlton’s appointment is a key step in that effort, and I am delighted to welcome her to the Company. I believe that Dr. Charlton’s addition, as well as her experience and knowledge of the inner workings of the fuel cycle will prove to be incredibly important as we continue to put together the building blocks for our next stages of growth.”

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS^™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR^™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR^™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “future,” “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements relate to the anticipated benefits of Dr. Charlton joining the Company, as well as the Company’s vertical integration and other operational plans and goals. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear’s control, as well as the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Attachment

• NANO Nuclear Energy Inc.

Multi-year framework consolidates IT expertise supply for two Dutch ministries and the national healthcare authority and represents the largest annualized contract in Circle8 Netherlands’ portfolio

ENGLEWOOD CLIFFS, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Circle8 Group, Inc. (Nasdaq: CIRC) today announced that its Dutch operating company, Circle8 Netherlands, has signed a four-year contract covering the Dutch Ministry of Health, Welfare and Sport, the Ministry of Social Affairs and Employment, and the Dutch Healthcare Authority. The contract has a total value of approximately $492 million over its four-year term.

The agreement consolidates the supply of IT expertise to all three government bodies under a single contractual framework. The contract commenced October 1, 2026, and runs through September 30, 2030, with seven contractors deployed at commencement.

The new framework is a continuation and expansion of existing arrangements and represents the largest annualized contract in Circle8 Netherlands’ portfolio. It further strengthens Circle8’s position in the Dutch public sector and provides a multi-year framework through which Circle8 Netherlands can continue supporting critical technology and workforce requirements across major government institutions.

“This agreement is an important milestone for Circle8 and demonstrates the strength of our platform, our long-standing relationships and our ability to execute large-scale, multi-year programs for sophisticated public-sector clients,” said Guus Franke, Chairman and Chief Executive Officer of Circle8 Group. “A $492 million framework across three important Dutch government bodies provides meaningful long-term visibility for our Netherlands business and reinforces our strategy of building durable customer relationships, expanding recurring revenue opportunities and delivering higher-value technology and workforce solutions across Europe and North America.”

“Three government bodies under one framework creates a more efficient structure for our clients and a significant long-term opportunity for Circle8,” said Patrick Schuijt, Chief Revenue Officer of Circle8. “The agreement builds on established relationships and gives us a strong platform to continue expanding the technology expertise we provide across the Dutch public sector.”

Consolidation of public-sector technology and workforce supply under multi-year frameworks is an established procurement model in the Netherlands and an important growth channel for Circle8’s Dutch operations. Circle8 believes its scale, specialist network and technology capabilities position the Company to compete effectively for these complex, long-duration programs.

About Circle8
Circle8 Group, Inc. (Nasdaq: CIRC) is an international technology, workforce and business transformation platform operating across North America and Europe.

Through its portfolio of specialist operating companies, Circle8 delivers technology consulting, artificial intelligence, cybersecurity, cloud, software engineering, engineering, managed services and workforce solutions to enterprise and public-sector organizations. The Company supports clients in designing, building, securing and operating mission-critical technology environments while helping organizations execute complex business and digital transformation programs.

With annualized revenue exceeding US$1.2 billion, more than 16,000 specialists, and operations across North America and Europe, Circle8 is building a scalable platform focused on recurring revenue, higher-value technology services, disciplined acquisitions and long-term shareholder value.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future growth, recurring revenue, strategic initiatives, acquisitions, customer relationships, market opportunities and business performance. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for a discussion of these risks and uncertainties. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Investor Contact
Kevin Murphy
Chief Financial Officer
kmurphy@atlantic-international.com

HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here.

The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist and T1D advocate Alisa Weilerstein. Together, they will join company management to discuss:

• Ongoing challenges for individuals living with T1D and the current treatment landscape
• Hypoglycemia risk and the experience of living with T1D
• Cadisegliatin, vTv’s novel, potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin in T1D
• An overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D with topline data expected in mid 2027

A live question-and-answer session will follow the formal presentations. Following the event, a replay will be available in the Investor Relations section of the Company’s website.

About Schafer Boeder, MD
Schafer Boeder, MD, is a board-certified endocrinologist, Medical Director at Paradigm Clinical Research, and Associate Professor of Medicine at the University of California San Diego. His clinical research focuses on the development of new medications, devices, and technologies for diabetes, obesity, and related metabolic diseases. He has served as principal investigator for numerous industry-, NIH-, and nonprofit-sponsored clinical trials and has published extensively in diabetes and metabolism. Dr. Boeder earned his medical degree from Eastern Virginia Medical School and completed his residency in internal medicine and fellowship in endocrinology, diabetes, and metabolism at UC San Diego.

About Klara Klein, MD, PhD
Klara Klein, MD, PhD, is an Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill and Director of the Endocrine Diabetes and Obesity Clinical Research Unit (EnDO CRU). A clinician-scientist, Dr. Klein oversees industry-sponsored and investigator-initiated clinical trials in metabolic diseases. Her research interests include atypical diabetes, diabetes in advanced chronic kidney disease, and stakeholder-engaged clinical trials designed to improve the reach and representativeness of clinical research. Dr. Klein is also actively involved in type 1 diabetes research and is a co-author of the UpToDate clinical topic on glycemic management in adults with type 1 diabetes.

About Alisa Weilerstein
Alisa Weilerstein is one of the foremost cellists of our time and an advocate for the T1D community. Diagnosed at age nine, she serves as a consultant to biotechnology company eGenesis and as a Celebrity Ambassador for Breakthrough T1D (formerly Juvenile Diabetes Research Foundation), the world leader in T1D research. Since making her professional debut in her early teens, she has appeared as a soloist, recitalist and chamber musician worldwide. She received a MacArthur Fellowship in 2011 and is known for her interpretations of Bach’s unaccompanied cello suites, award-winning recordings and championing of contemporary music.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.

About Cadisegliatin  
Cadisegliatin (TTP399) is a novel, oral small-molecule, glucokinase activator being investigated in the U.S. as a potential first-in-class adjunctive treatment for T1D. In nonclinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).  

Cadisegliatin is under investigation, and its safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.  

Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

Key highlights

• Rezolve Ai presents its strategy, growth drivers and full agentic commerce stack to investors today at Nasdaq MarketSite, with live product demonstrations; investors can register here to join online.
• Rezolve Ai’s US AI Visibility Study 2026 finds that 97 of America’s 100 largest retailers publish no way for an AI agent to check out.
• Management will outline Rezolve Ai’s commercial progress, operating priorities and growth strategy as the Company demonstrates its full platform for the agentic commerce economy.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in agentic commerce and AI-powered customer engagement, today hosts its Investor Day at Nasdaq MarketSite in New York City. Management will give investors and analysts the first comprehensive presentation of how Rezolve Ai’s commerce, data and payments capabilities combine into a single platform for the agentic economy. The event is open to in-person and online attendees, who can register here.

To mark the event, Rezolve Ai today publishes the US AI Visibility Study 2026, which examines how the leading AI assistants present 2,047 US companies to consumers. The companies span every member of the S&P 500, all of the NRF Top 100 retailers, 60 large private companies, 362 consumer brands and more than 1,000 other US retailers and listed companies.

The study finds that one in four of these companies is never named by OpenAI, Claude, Perplexity or Gemini, including nearly one in five members of the S&P 500. AI assistants name companies most often while consumers browse, yet 97 of America’s 100 largest retailers publish no way for an AI agent to check out, including 13 that turned automated visitors away. Additionally, most LLMs build their answers almost entirely from third parties, with a company’s own website accounting for just 1.5% of the sources AI cites, and visibility differs from one assistant to the next.

“Every era of commerce has had a gatekeeper. For twenty years it was the search engine. Today it is the AI agent, and it is deciding which brands a customer hears about before they ever reach a store,” said Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai. “This research should be a wake-up call to every boardroom in America. The companies that win the next decade of commerce will be the ones that give AI something it can trust and transact with, and that is precisely what Rezolve Ai was built to provide.”

Rezolve Ai’s platform is designed to enable merchants to supply AI assistants with trusted answers drawn from their own catalog, live pricing and availability. Its agent-ready APIs are designed to help those assistants find products and complete purchases directly. Its commerce-trained brainpowa models interpret shopper intent, while Rezolve Commerce and agentic checkout convert that intent into a sale. Rezolve Pay supports payment optimization, and Rezolve Reward helps drive customer engagement and repeat purchasing.

Rezolve Ai takes the platform to market through three growth engines that reinforce one another: an expanding product suite, distribution through Microsoft, Google, TCS and Tech Mahindra, and the licensing of the data, intelligence and payment rails beneath it to platforms, banks and payment networks.

Investor Day Focus
At Investor Day, management will present Rezolve Ai’s strategy, market opportunity, commercial model and growth drivers. The presentation will focus on the Company’s platform, strategic partnerships, product roadmap, customer adoption, operating discipline and path toward long-term profitable growth. Live demonstrations will show how trusted data infrastructure, proprietary commerce intelligence, auditable agent workflows, customer engagement, transactions and payments connect across the platform.

“I founded Rezolve Ai to give digital commerce what the best stores have always had: an assistant who understands the customer and closes the sale,” said Wagner. “A decade later, AI agents are becoming the largest sales force commerce has ever known, and Rezolve Ai is the infrastructure backbone they run on. Today investors will see a business that has proven it can scale and is now turning that scale into profitability.”

Event details
Date: Tuesday, October 6, 2026
Location: Nasdaq MarketSite, New York City
Schedule: Networking breakfast from 9:00 a.m. EDT; opening remarks and live webcast from 9:45 a.m. EDT, concluding at approximately 1:00 p.m. EDT
Registration: Investors and analysts can attend in person or online and should pre-register at edge.media-server.com/mmc/p/hz8x6poa
Materials: The live webcast, replay and presentation materials will be available on Rezolve Ai’s investor relations website at investor.rezolve.com

About the US AI Visibility Study 2026
The study analyzed how OpenAI, Claude, Perplexity and Gemini, each with web search enabled, respond to unbranded consumer questions about the markets of 2,047 US companies drawn from six public lists, including the S&P 500 and the NRF Top 100. Fieldwork took place between September 23 and October 5, 2026. Full results and methodology are available at aeo-audit.rezolve.com/us.

About Rezolve Ai
Rezolve Ai is the infrastructure backbone powering AI-driven commerce for merchants, financial institutions, hyperscalers and technology companies. Its Brain Suite platform helps retailers, brands and financial institutions transform how consumers search, engage and transact across digital channels.

Rezolve Ai’s proprietary brainpowa™ models are purpose-built for commerce, while TraceWare™ is designed to provide transparency and accountability across agentic AI workflows. Together, Rezolve Ai’s technology enables enterprises to deploy AI that can engage customers, understand intent, support transactions and operate safely at scale.

Headquartered in London with operations across North America, Europe and Asia, Rezolve Ai partners with leading global enterprises to power the future of commerce through AI that sells. Learn more at rezolve.com.

Media contact
Urmee Khan, Group Director of Communications & Corporate Affairs, Rezolve Ai:
urmeekhan@rezolve.com
+44 7576 094 040

Forward-looking statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements about Rezolve Ai’s product plans, platform capabilities, strategic partnerships, market opportunity, growth strategy, profitability, Investor Day presentations and matters described in the U.S. AI Visibility Study 2026. These statements reflect management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described in Rezolve Ai’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Rezolve Ai undertakes no obligation to update them except as required by law.

Over 80 percent say their generation faces unique retirement challenges, with rising health care costs, inflation and Social Security uncertainty reshaping expectations for life after work

WEST DES MOINES, Iowa, Oct. 06, 2026 (GLOBE NEWSWIRE) — The retirement landscape has fundamentally changed for Gen X and Millennials, according to a new survey conducted by Harris Poll on behalf of Athene. Facing fewer pensions, greater market uncertainty and heightened concern about health care costs, inflation and Social Security, today’s pre-retirees are viewing and building a dramatically different model of retirement than the generations before them.

More than eight in 10 respondents (83%) say their generation faces retirement challenges previous generations did not, while 76% believe the U.S. retirement system was designed for a previous generation. Nearly two-thirds (61%) say they have fewer guaranteed retirement-income options than prior generations, and 63% are concerned Social Security will run out of funds before they begin collecting benefits.

“Greater awareness of the need for retirement savings means that the biggest questions most retirement savers face today are whether they will outlive their savings and how they can turn their savings into reliable income that lasts,” said Sean Brennan, Co-President, Athene USA. “Retirement savers have fewer traditional sources of guaranteed income, such as pensions, while managing greater uncertainty in this economic environment. Gen X and Millennials are looking for solutions to help navigate their future with confidence, flexibility and a greater sense of control over their financial futures.”

Rising Costs Create a New Set of Retirement Pressures

The survey of more than 2,000 U.S. adults ages 40–61 with at least $100,000 in investable assets and household income of $50,000 or more highlights the economic uncertainty regarding preparation and expectations for retirement. The top concern – two-thirds of respondents (67%) – is rising health care costs while 62% cite inflation as a major concern.

Those pressures are already influencing the ability to save. Half of respondents (50%) identify inflation as a top barrier to retirement saving, followed by day-to-day expenses (39%) and health care costs (32%).

Guaranteed Income Has Wide Appeal, but Is Not Widely Understood

The findings point to a significant opportunity to help retirement savers better understand options for creating dependable retirement income. Eighty-six percent of those who know what annuities are say they offer benefits that are appealing. Yet only 23% have purchased an annuity. However, with greater understanding, 80% say they would consider purchasing an annuity if they knew more about them. At the same time, more than half (53%) say annuities are too complex.

“These findings reinforce the broad appeal of guaranteed income solutions, as well as the need to create greater understanding of their benefits,” said Mike Downing, Co-President, Athene USA. “Annuities are a vital retirement tool that can complement savings, investments and Social Security to create a more resilient retirement plan.”

While respondents express a desire for security, their retirement plans often remain incomplete. Only 40% say they have planned for how to convert their accumulated savings into income in retirement, and just 29% say they have fully accounted for the length of their retirement in their financial planning. In addition, 85% of survey respondents found guaranteed monthly income through a 401(k) appealing, demonstrating a clear desire for pension-like features in the defined contribution ecosystem.

“Retirement savers shouldn’t need to become investment experts on the day they retire,” said Rebecca Tadikonda, CEO, Vitera. “Retirees need solutions that simplify their transition from saving to spending so they can confidently enjoy the retirement they worked hard for.”

Despite the challenges, respondents remain cautiously optimistic about their own financial security in retirement. Thirty-eight percent say they are somewhat confident in their ability to achieve retirement financial security, while 32% are very confident and 21% are extremely confident. Nine percent say they are not at all confident.

Methodology

This survey was conducted online within the United States by Harris Poll on behalf of Athene from June 26 through July 7, 2026, among 2,022 U.S. residents ages 40–61 with at least $100,000 in investable assets and household income of at least $50,000. Results have been weighted where necessary to bring them into line with their actual proportions in the population.

About Athene

Athene is the leading retirement solutions company with $473 billion of total assets as of June 30, 2026, and operations in the United States, Bermuda, Canada, and Japan. Athene is focused on providing financial security to individuals by offering an attractive suite of retirement income and savings products and also serves as a solutions provider to corporations. For more information, please visit www.athene.com.

Contact

Alyssa Castelli
Director, External Relations
+1 (646) 768-7304
Alyssa.castelli@athene.com

Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort. The event will provide an overview of the PDS0301 trial in patients with second and third line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases. These MSS patients constitute the majority of mCRC, a population in which immunotherapy has been mostly ineffective.

PDS0301 is an investigational IL-12 immunocytokine designed using an antibody that binds to necrotic DNA that is found within tumors. PDS0301 specifically targets and delivers the IL-12 into the tumor to promote T cell and natural killer (NK) cell infiltration into the tumor, as well as localized anti-tumor activation of both T cells and NK cells.

A live question and answer session will follow the formal presentations.

Register & Attend

Date:	Thursday, October 15, 2026
Time:	8:00 AM ET
Registration:	Click Here

Jonathan M. Hernandez, M.D., Investigator, Surgical Oncology Program, NCI/CCR

Dr. Hernandez graduated from medical school with honors from the University of Florida and completed general surgery training at the University of South Florida. During his residency, Dr. Hernandez spent two years at the Moffitt Cancer Center and Research Institute interrogating molecular diagnostics for liver metastases and miRNA-mediated mechanisms of metastatic spread. Following residency, Dr. Hernandez completed fellowship training in both surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center. During his fellowships, Dr. Hernandez spent an additional two years in dedicated basic research studying metastatic colonization as a scholar in the Cell Biology Program of the Sloan Kettering Institute and as a visiting investigator in the Cell and Developmental Biology Department of Weill Medical College of Cornell University. The Hernandez lab studies hepatic metastases and has been the home to twenty surgical residents since its establishment at the NIH in 2016. Dr. Hernandez has authored over 175 peer-reviewed publications and has contributed book chapters in numerous authoritative surgical texts.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. PDS Biotechnology owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.

The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune^® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  
Versamune^® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)

MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities.

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated in the financing.

DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, representing approximately 5.0% of Telomir’s outstanding common stock. His additional $1.0 million investment further increases his investment in Telomir as the Company advances its lead program into clinical development.

“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir,” said John Paul DeJoria. “Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”

Alexander Capital, L.P. acted as placement agent for the financing. The Company expects to receive aggregate gross proceeds of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Financing Terms

Under the terms of the financing, Telomir issued 4,843,300 shares of common stock at a purchase price of $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price (VWAP). The financing resulted in aggregate gross proceeds to the Company of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Investors in the financing purchased common stock at a fixed price, with no accompanying investor warrants, convertible securities, or variable-price or reset features.

The securities were issued in a private placement. Telomir has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued in the financing, subject to the terms of the Registration Rights Agreement.

The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.

“We have been very deliberate about how and when we access the capital markets,” said Erez Aminov, Chairman and CEO of Telomir. “Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”

Strengthening Telomir’s Position for Clinical Execution

The financing comes as Telomir advances Telomir-Zn, its lead investigational oral small molecule, into human clinical evaluation. The U.S. Food and Drug Administration has cleared Telomir’s Investigational New Drug (IND) application for Telomir-Zn, enabling the Company to proceed with its first-in-human Phase 1/2 clinical trial in patients with advanced or metastatic TNBC.

TNBC is an aggressive form of breast cancer defined by the absence of three common therapeutic targets, estrogen receptors, progesterone receptors, and HER2, limiting the applicability of many targeted treatments used in other forms of breast cancer. Patients with advanced or metastatic disease continue to face a significant need for additional treatment options.

The multicenter, open-label Phase 1/2 study is designed to move Telomir-Zn from initial human dosing through dose selection and into an efficacy-focused expansion. The Phase 1 portion will evaluate safety, tolerability, and dose selection while also assessing pharmacodynamic biomarkers and preliminary signals of antitumor activity. The Phase 2 expansion is designed to build on those findings with a greater focus on efficacy, providing an initial clinical proof-of-concept assessment of Telomir-Zn in advanced or metastatic TNBC.

A New Epigenetic Approach to Treating Cancer

Telomir-Zn is being developed as a potentially first-in-class oral epigenetic therapy designed to modulate intracellular metal homeostasis, particularly iron and copper, and influence gene-control pathways implicated in cancer. Preclinical studies have demonstrated inhibition of multiple iron-dependent histone demethylases (KDMs), supporting the Company’s hypothesis that Telomir-Zn may help restore more normal epigenetic regulation and potentially reactivate tumor-suppressor pathways that cancer has silenced.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Private Placement Disclosure

The securities described in this press release are being offered and sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement, subject to the terms and conditions of the applicable registration rights agreement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

SPRINGFIELD, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the fourth quarter ended July 25, 2026.

Fourth Quarter of Fiscal 2026 Highlights

• Net income of $13.6 million, or $0.92 per Class A diluted share
• Sales and same store sales each increased 1.6%
• Same store digital sales increased approximately 6%

Year-To-Date Fiscal 2026 Highlights

• Net income of $52.5 million, or $3.54 per Class A diluted share
• Sales increased 3.7% and same store sales increased 2.2%
• Same store digital sales increased approximately 11%

Fourth Quarter of Fiscal 2026 Results

Sales were $609.6 million in the 13 weeks ended July 25, 2026 compared to $599.7 million in the 13 weeks ended July 26, 2025. Sales increased due primarily to same store sales growth of 1.6% and the opening of our East Orange, NJ replacement store on May 27, 2026. Same store sales increased due primarily to digital sales growth, strong performance in fresh and pharmacy departments, and continued growth in recently remodeled and replacement stores. These increases were partially offset by egg price deflation, competitive store openings and sales cannibalization from the East Orange replacement store. New stores, replacement stores and stores with banner changes are included in same store sales in the quarter after the store has been in operation for four full quarters. Store renovations and expansions are included in same store sales immediately.

Gross profit as a percentage of sales increased to 28.24% in the 13 weeks ended July 25, 2026 compared to 28.17% in the 13 weeks ended July 26, 2025 due primarily to increased departmental gross margin percentages (.28%), largely offset by an unfavorable change in product mix (.08%), lower patronage dividends and other rebates received from Wakefern (.04%), increased promotional spending (.04%) and increased warehouse assessment charges from Wakefern (.03%). The increase in department gross margin is due primarily to improvements in shrink and commissary operations.

Operating and administrative expense as a percentage of sales increased to 23.92% in the 13 weeks ended July 25, 2026 compared to 23.11% in the 13 weeks ended July 26, 2025. Adjusted operating and administrative expense as a percentage of sales increased to 23.92% in the 13 weeks ended July 25, 2026 compared to 23.34% in the 13 weeks ended July 26, 2025. The increase in Adjusted operating and administrative expense is due primarily to higher employee costs (.16%), store pre-opening costs (.09%), external service, technology and payment processing costs (.08%), occupancy costs (.08%), facility insurance premiums (.07%), legal and other professional fees (.06%), and non-recurring costs associated with fire and power outage incidents (.05%). These increases were partially offset by lower advertising costs (.07%).

Depreciation and amortization expense increased in the 13 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to capital expenditures.

Interest expense decreased in the 13 weeks ended July 25, 2026 compared to the comparative prior year fiscal period due primarily to lower average outstanding debt balances.

Interest income decreased in the 13 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower interest rates on variable rate notes receivable from Wakefern and demand deposits invested at Wakefern.

The Company’s effective income tax rate was 30.6% in the 13 weeks ended July 25, 2026 compared to 31.4% in the 13 weeks ended July 26, 2025.

Net income was $13.6 million in the 13 weeks ended July 25, 2026 compared to $15.5 million in the 13 weeks ended July 26, 2025. Adjusted net income was $13.6 million in the 13 weeks ended July 25, 2026 compared to $15.6 million in the 13 weeks ended July 26, 2025.

Year-To-Date Fiscal 2026 Results

Sales were $2.406 billion in the 52 weeks ended July 25, 2026 compared to $2.321 billion in the 52 weeks ended July 26, 2025. Sales increased due primarily to same store sales growth of 2.2% and the openings of the Watchung, NJ and East Orange, NJ replacement stores on April 9, 2025 and May 27, 2026, respectively. Same store sales increased due primarily to digital sales growth, strong performance in fresh and pharmacy departments, and continued growth in remodeled and replacement stores. These increases were partially offset by egg price deflation and sales cannibalization from the Watchung replacement store.

Gross profit as a percentage of sales decreased to 28.17% in the 52 weeks ended July 25, 2026 compared to 28.57% in the 52 weeks ended July 26, 2025 due primarily to lower patronage dividends and other rebates received from Wakefern (.32%), an unfavorable change in product mix (.07%) and increased promotional spending (.05%), partially offset by increased departmental gross margin percentages (.07%).

Operating and administrative expense as a percentage of sales increased to 24.06% in the 52 weeks ended July 25, 2026 compared to 23.92% in the 52 weeks ended July 26, 2025. Adjusted operating and administrative expense as a percentage of sales increased to 24.05% in the 52 weeks ended July 25, 2026 compared to 23.98% in the 52 weeks ended July 26, 2025. The increase in Adjusted operating and administrative expense is due primarily to higher legal and other professional fees (.12%), utility, repair and maintenance costs (.10%), facility insurance costs (.06%) and store pre-opening costs (.06%). These increases were largely offset by lower employee costs (.13%), lower advertising costs (.10%) and short-term rental income (.05%).

Depreciation and amortization expense increased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to capital expenditures.

Interest expense decreased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower average outstanding debt balances.

Interest income decreased in the 52 weeks ended July 25, 2026 compared to the comparative prior fiscal year period due primarily to lower interest rates on variable rate notes receivable from Wakefern and demand deposits invested at Wakefern.

The Company’s effective income tax rate was 28.8% in the 52 weeks ended July 25, 2026 compared to 31.1% in the 52 weeks ended July 26, 2025. The decline in the effective tax rate was primarily due to the excess tax benefit from vested stock-based compensation in the 52 weeks ended July 25, 2026.

Net income was $52.5 million in the 52 weeks ended July 25, 2026 compared to $56.4 million in the 52 weeks ended July 26, 2025. Adjusted net income was $52.7 million in the 52 weeks ended July 25, 2026 compared to $56.4 million in the 52 weeks ended July 26, 2025.

Village Super Market, Inc. operates a chain of 34 supermarkets in New Jersey, New York, Maryland and Pennsylvania under the ShopRite and Fairway banners and three Gourmet Garage specialty markets in New York City.

Forward Looking Statements

All statements, other than statements of historical fact, included in this Press Release are or may be considered forward-looking statements within the meaning of federal securities law. The Company cautions the reader that there is no assurance that actual results or business conditions will not differ materially from future results, whether expressed, suggested or implied by such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect developments or information obtained after the date hereof. The following are among the principal factors that could cause actual results to differ from the forward-looking statements: general economic conditions; competitive pressures from the Company’s operating environment; the ability of the Company to maintain and improve its sales and margins; the ability to attract and retain qualified associates; the availability of new store locations; the availability of capital; the liquidity of the Company; the success of operating initiatives; consumer spending patterns; the impact of changing energy prices; increased cost of goods sold, including increased costs from the Company’s principal supplier, Wakefern; disruptions or changes in Wakefern’s operations; the results of litigation; the results of tax examinations; the results of union contract negotiations; competitive store openings and closings; labor shortages; disruptions to supply chains; and other factors detailed herein and in the Company’s filings with the SEC.

The Company’s consolidated financial statements are presented in accordance with generally accepted accounting principles (“GAAP”). We provide non-GAAP measures, including Adjusted net income and Adjusted operating and administrative expenses as management believes these supplemental measures are useful to investors and analysts. These non-GAAP financial measures should not be reviewed in isolation or considered as a substitute for our financial results as reported in accordance with GAAP, nor as an alternative to net income, operating and administrative expense or any other GAAP measure of performance. Management believes Adjusted net income and Adjusted operating and administrative expense are useful to investors because they provide supplemental measures that exclude the financial impact of certain items that affect period-to-period comparability. Management and the Board of Directors use these measures as they provide greater transparency in assessing ongoing operating performance on a period-to-period basis. Other companies may have different definitions of non-GAAP measures and provide for different adjustments, and comparability to the Company’s results of operations may be impacted by such differences. The Company’s presentation of non-GAAP measures should not be construed as an implication that its future results will be unaffected by unusual or non-recurring items.

VILLAGE SUPER MARKET, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited)
	13 Weeks Ended								52 Weeks Ended
	July 25, 2026				July 26, 2025				July 25, 2026				July 26, 2025
Sales	$	609,568			$	599,674			$	2,405,707			$	2,320,690
Cost of sales		437,453				430,773				1,727,956				1,657,724
Gross profit		172,115				168,901				677,751				662,966
Operating and administrative expense		145,825				138,581				578,928				555,038
Depreciation and amortization expense		8,944				8,640				34,507				34,398
Impairment of assets		—				1,462				—				1,462
Operating income		17,346				20,218				64,316				72,068
Interest expense		839				879				3,382				3,751
Interest income		(3,117	)			(3,274	)			(12,689	)			(13,502	)
Income before income taxes		19,624				22,613				73,623				81,819
Income taxes		6,007				7,093				21,168				25,439
Net income	$	13,617			$	15,520			$	52,455			$	56,380
Net income per share:
Class A common stock:
Basic	$	1.02			$	1.17			$	3.94			$	4.24
Diluted		0.92				1.05				3.54				3.81
Class B common stock:
Basic	$	0.66			$	0.76			$	2.56			$	2.75
Diluted		0.66				0.76				2.56				2.75
Gross profit as a % of sales		28.24	%			28.17	%			28.17	%			28.57	%
Operating and administrative expense as a % of sales		23.92	%			23.11	%			24.06	%			23.92	%

VILLAGE SUPER MARKET, INC.
RECONCILIATION OF NON-GAAP MEASURES
(In thousands) (Unaudited)

The following table reconciles Net income to Adjusted net income and Operating and administrative expenses to Adjusted operating and administrative expenses:

	13 Weeks Ended								52 Weeks Ended
	July 25, 2026				July 26, 2025				July 25, 2026				July 26, 2025
Net Income	$	13,617			$	15,520			$	52,455			$	56,380
Adjustments to Operating and Administrative Expenses:
Pension settlement charge (gain) (1)		—				(874	)			338				(874	)
Rent concession (2)		—				(517	)			—				(517	)
Adjustments to Impairment of Assets:
Impairment of assets (3)		—				1,462				—				1,462
Adjustments to Income Taxes:
Tax impact of special items		—				(22	)			(105	)			(22	)
Adjusted net income	$	13,617			$	15,569			$	52,688			$	56,429
Operating and administrative expenses	$	145,825			$	138,581			$	578,928			$	555,038
Adjustments to operating and administrative expenses		—				1,391				(338	)			1,391
Adjusted operating and administrative expenses	$	145,825			$	139,972			$	578,590			$	556,429
Adjusted operating and administrative expenses as a % of sales		23.92	%			23.34	%			24.05	%			23.98	%

(1) Fiscal 2026 pension settlement charge relates to the termination of a Company-sponsored plan. Fiscal 2025 pension settlement gain relates to lump payments made under an unfunded, non-qualified company sponsored defined benefit plan. 
(2) Fiscal 2025 includes income related to rent concessions received on one store location to compensate for disruption in operations during redevelopment of the retail center. 
(3) Fiscal 2025 includes non-cash impairment charges on the long-lived assets of one Gourmet Garage store and real estate assets classified as held for sale.

Contact:	John Van Orden, CFO
	(973) 467-2200
	villageinvestorrelations@wakefern.com

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,151,990	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,151,990	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	1,480	230.01p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,151,990	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,151,990	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	1,480	230.01p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.